Intravenous and oral phamacokinetic and pharmacodynamic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor

被引：0
|
作者：
Kilpatrick, JM
Harman, L
Phillips, D
Zhang, JW
Morris, P
Bukowski, R
Thomas, D
机构：
[1] BioCryst Pharmaceut Co, Birmingham, AL 35007 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] MD Anderson Canc Clin, Houston, TX USA
来源：
FASEB JOURNAL | 2004年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A605 / A605
页数：1
相关论文
共 40 条
  • [1] Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor.: In vivo effects on blood 2′-deoxyguanosine in primates
    Kilpatrick, JM
    Morris, PE
    Serota, DG
    Phillips, D
    Moore, DR
    Bennett, JC
    Babu, YS
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2003, 3 (04) : 541 - 548
  • [2] A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)
    Gandhi, V
    Kilpatrick, JM
    Plunkett, W
    Ayres, M
    Harman, L
    Du, M
    Bantia, S
    Davisson, J
    Wierda, WG
    Faderl, S
    Kantarjian, H
    Thomas, D
    BLOOD, 2005, 106 (13) : 4253 - 4260
  • [3] Purine nucleoside phosphorylase inhibitor BCX-1777 (immucillin-H) - a novel potent and orally active immunosuppressive agent
    Bantia, S
    Miller, PJ
    Parker, CD
    Ananth, SL
    Horn, LL
    Kilpatrick, JM
    Morris, PE
    Hutchison, TL
    Montgomery, JA
    Sandhu, JS
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (06) : 1199 - 1210
  • [4] Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma.
    Duvic, M
    Foss, FM
    Olsen, EA
    Forero-Torres, A
    Bennett, JC
    Bantia, S
    Kilpatrick, JM
    BLOOD, 2004, 104 (11) : 683A - 683A
  • [5] Synthesis of deuterated-BCX-1777, a potent inhibitor of purine nucleoside phosphorylase
    Kezar, HS
    Hutchison, TL
    Tyler, PC
    Morris, PE
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2002, 45 (01): : 71 - 78
  • [6] PURINE NUCLEOSIDE PHOSPHORYLASE - TRANSITION-STATE ANALYSIS
    KLINE, PC
    SCHRAMM, VL
    FASEB JOURNAL, 1992, 6 (01): : A38 - A38
  • [7] Antileukemic activity and pharmacodynamics of intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, in phase I/II trials in patients with advanced T-cell malignancies
    Isola, L
    Furman, RR
    Gandhi, V
    Thomas, DA
    Bennett, JC
    Bantia, S
    Kilpatrick, JM
    BLOOD, 2004, 104 (11) : 208B - 209B
  • [8] PURINE NUCLEOSIDE PHOSPHORYLASE - MECHANISM AND TRANSITION-STATE ANALYSIS
    KLINE, PC
    SCHRAMM, VL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1991, 202 : 46 - BIOL
  • [9] PURINE NUCLEOSIDE PHOSPHORYLASE - MECHANISM AND TRANSITION-STATE ANALYSIS
    KLINE, PC
    SCHRAMM, VL
    FASEB JOURNAL, 1993, 7 (07): : A1064 - A1064
  • [10] Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia.
    Furman, RR
    Gandhi, VV
    Bennett, JC
    Bantia, S
    Kilpatrick, JM
    BLOOD, 2004, 104 (11) : 750A - 750A
1234